Repositrak, Inc. annual report, FY2015

Filing scope and business context

The supplied filing is Park City Group, Inc.’s Form 10-K for the fiscal year ended June 30, 2015—not a standalone ReposiTrak, Inc. filing or a 2014 quarterly report. ReposiTrak became Park City Group’s wholly owned subsidiary on June 30, 2015, so its operating results were not consolidated for the year apart from that date. Unless otherwise noted, amounts below are U.S. dollars.

Park City Group provides supply-chain and retail software principally through a subscription-based SaaS model, alongside licenses, support and professional services. ReposiTrak’s food-safety, regulatory-compliance and traceability platform expanded the product offering.

Financial performance and position

Metric	FY ended June 30, 2015	FY ended June 30, 2014
Revenue	$13.65 million	$11.93 million
Operating loss	$4.09 million	$2.59 million
Net loss	$3.85 million	$2.49 million
Net loss applicable to common shareholders	$6.56 million	$3.11 million
Cash from operating activities	$1.71 million	$(0.09) million

• Revenue grew 14%, or $1.72 million. Subscription revenue increased $1.48 million; management attributed the remainder primarily to ReposiTrak-related service fees.
• Subscriptions were approximately $10.9 million, or 80% of revenue, versus a historical mix increasingly shifted away from one-time licenses. Cost of services was 39% of revenue versus 43% in FY2014; implied gross margin was approximately 61% versus 57%.
• Operating expenses rose to $17.74 million from $14.52 million. Sales and marketing increased 25% to $5.94 million, and general and administrative expense increased 12% to $4.28 million. A $1.50 million non-cash impairment of customer relationships also contributed to the operating loss. Operating margin was approximately -30% versus -22%.
• Net loss margin was approximately -28% versus -21%. FY2015 included $568,821 of preferred dividends and a $2.14 million Series B restructuring charge deducted in calculating loss attributable to common shareholders; therefore, that shareholder loss exceeds the reported net loss.
• Cash and cash equivalents were $11.33 million at year-end, up from $3.35 million. Working capital was $5.03 million, versus $0.65 million. Cash increased largely due to equity financing, not operating cash generation alone.
• Investing activities used $2.61 million, including advances to ReposiTrak before acquisition; financing activities provided $8.87 million. Stock-based compensation of $2.76 million was a significant non-cash expense.
• Total debt, as presented in selected financial data, was $3.08 million, including a $2.50 million bank line of credit and $576,493 of notes payable. The line matured May 15, 2016; notes payable were $227,301 current and $349,192 long term. Total liabilities were $8.82 million.

Material changes and transactions

• On June 30, 2015, Park City Group acquired all ReposiTrak shares in exchange for 873,438 Park City Group common shares, valued at approximately $10.82 million. The acquisition accounting included approximately $15.39 million of goodwill and $2.01 million of customer relationships; these valuations were provisional pending a third-party valuation.
• Before closing, Park City Group recorded approximately $3.0 million in ReposiTrak subscription and management fees, reported as approximately 21% of FY2015 revenue. It advanced approximately $2.3 million net for ReposiTrak working capital; related notes were eliminated on consolidation.
• The April 2015 registered direct offering raised approximately $6.7 million net from 572,500 shares. A January private placement raised approximately $0.9 million gross. These financings materially strengthened year-end cash and working capital but increased share dilution.
• The Series B preferred restructuring reduced the stated dividend rate from 15% to 7% if paid in cash or 9% if paid in additional preferred shares, removed the conversion feature, and included additional preferred shares and warrants. Preferred dividends continued to accrue; $442,002 of FY2015 dividends were paid in Series B-1 shares.
• Revenue grew more quickly than in FY2014 (14% versus 5%), but losses widened. Operating cash flow turned positive from a small use of cash in FY2014.

Outlook, risks and other notable items

• Management expected revenue to increase in FY2016 and later, citing supplier connections to existing retail customers and subscription payments from ReposiTrak customers. It expected sales and marketing expense to remain at current levels to support growth. These are expectations, not quantified guidance.
• Management stated existing cash and expected operating cash flow should fund operations and debt obligations for at least 12 months, while noting that future capital needs depend on growth, sales and marketing, product development and market acceptance. The filing cautions that continued losses could consume cash and future financing may not be available on acceptable terms.
• Key risks include achieving subscription growth and renewals, successfully integrating and growing ReposiTrak, customer concentration related to ReposiTrak, competition and technology changes, service interruptions or security breaches, product errors and potential claims associated with food recalls. The company also disclosed substantial influence by its CEO and directors and potential dilution from preferred stock, warrants and future share issuances.
• No pending or threatened legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements and internal controls; management also concluded internal control over financial reporting was effective.

Important facts for investors to verify

• Confirm the reporting scope and period: this is Park City Group’s FY2015 10-K, with ReposiTrak acquired on the final day of the year—not ReposiTrak’s standalone 2014 quarterly report.
• Assess whether recurring subscription growth and ReposiTrak customer subscriptions can offset operating losses and high sales and marketing costs.
• Review the acquisition’s final valuation, particularly provisional goodwill and customer-relationship values, and the resulting impairment risk.
• Check the terms, maturity and refinancing or repayment status of the $2.5 million credit line and other debt, as well as preferred dividend accruals and warrant dilution.
• Reconcile reported cash generation with financing proceeds, ReposiTrak advances and non-cash expenses when assessing liquidity and operating performance.